Oncology

Cancer cells
#Cancer Research UK #Collaboration #Oncology #ORIC Pharmaceuticals

Cancer Research UK and ORIC partner on CIP2A-targeted therapy

Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.  Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More

#Cancer Research #News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

Dollar sign on a tablet
#Collaboration #KRAS #MSD #Oncology #SciBrunch Therapeutics

MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion

SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.  Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.   SciBrunch will receive an upfront payment of $400… Read More

#Business & Investment #News

Multiple myeloma
#Cancer research #Chimagen Biosciences #GSK #Multiple myeloma #Oncology

GSK to acquire potential asset for multiple myeloma  

GSK has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter Phase I trials in 2027.  TCEs have shown… Read More

#News

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Ona Therapeutics #Oncology #Phase I trial

Ona Therapeutics moves to Phase I with ADC for advanced cancers

Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers.   The company says that more than half of the patients planned for the study have already been enrolled, with the trial continuing to… Read More

#Cancer Research #News

#Big Picture Bio #Combination therapy #Financing #Innovate UK #Oncology #Start-ups

Deep Science Ventures veterans launch Big Picture Bio

A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding.  Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how tumours, immune cells… Read More

#Business & Investment #News #Start-up Zone

Lung cancer
#Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Amivantamab shown to extend survival in advanced NSCLC

Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab).  The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More

#Cancer Research #News #Trending News

GPCRs
#Drug discovery #GPCRs #Oncology

eBook: Insights into GPCR drug discovery & development 

G protein-coupled receptors (GPCRs) form one of the largest drug target families, with 516 approved drugs targeting GPCRs. They play a central role in cellular signalling pathways, including neurotransmission, immune response and metabolic regulation, making them key targets for therapeutic intervention. Currently approved drugs act on 121 GPCR… Read More

#News

Cancer cells
#Drug discovery #Epigenetics #Genomics #Oncology

How Oryzon Genomics is using epigenetics to tackle cancer  

DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development.   RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses?  CB: Yes. Many aggressive cancers are driven not only by gene mutations, but by the… Read More

#Exclusive Content

Head and neck cancer
#Head and neck cancer #Oncology #Phase II trial #QBiotics

Phase II data show durable responses in head and neck cancer

QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.   The company says the result, based on 14 responses across 18… Read More

#Cancer Research #News

#Cancer vaccine #Head and neck cancer #NEC Corporation #Oncology #Phase I trial #Transgene

100% three-year disease-free survival in head and neck cancer

Transgene and NEC Corporation have reported sustained 100% three-year disease-free survival (DFS) in patients treated with TG4050 in the Phase I part of a randomised Phase I/II trial.   TG4050 is the first individualised neoantigen therapeutic vaccine (INTV) based on the myvac platform.  It is… Read More

#Cancer Research #Editor's Choice #News

T cells
#Collaboration #Evotec #Oncology #Plectonic Biotech #T cell engagers

Partners explore T cell engaging approaches for solid tumours

Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours.   The collaboration aims to address key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumours by combining Plectonic’s programmable LOGIBODY technology with Evotec’s… Read More

#Business & Investment #Cancer Research #News

Female researcher in a laboratory
#Oncology #PROTAC #University of Edinburgh

Protein build-up may shape cancer drug response, study finds

The way cancer-causing proteins accumulate in tumours may influence how effectively Proteolysis Targeting Chimeras (PROTAC) drugs can remove them, a new study suggests.   Researchers found that PROTACs were more effective at removing proteins that build up because they are not broken down properly than proteins that cancer… Read More

#Cancer Research #News

Targetted cancer therapy
#Interview #Oncology #Precision medicine #Racura Oncology

Why G‑quadruplex biology is back and what it means for MYC‑driven cancers

Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients.  Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about the company’s approach… Read More

#Cancer Research #Exclusive Content